NASDAQ:AMAG AMAG Pharmaceuticals (AMAG) Stock Price, News & Analysis → The asset beating inflation by 4x (From Colonial Metals) (Ad) Free AMAG Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$13.75▼$13.7550-Day Range$13.69▼$13.7552-Week Range$4.41▼$13.80VolumeN/AAverage Volume950,664 shsMarket Capitalization$477.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get AMAG Pharmaceuticals alerts: Email Address Ad Porter & CompanyKiss of death from Joe BidenBiden cannot lose this election. A bombshell new documentary exposes how the D.C establishment has engineered an “electoral failsafe” that all but guarantees Democratic victory… not just in 2024 but every future election.I have uncovered a bombshell that changes everything… and threatens everything. About AMAG Pharmaceuticals Stock (NASDAQ:AMAG)AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.Read More Ad Porter & CompanyKiss of death from Joe BidenBiden cannot lose this election. A bombshell new documentary exposes how the D.C establishment has engineered an “electoral failsafe” that all but guarantees Democratic victory… not just in 2024 but every future election.I have uncovered a bombshell that changes everything… and threatens everything. AMAG Stock News HeadlinesMay 14, 2024 | finance.yahoo.comGlobal Iron Drugs Strategic Business Report 2024: Market to Reach $11 Billion by 2030 with Oral Segment to Account for $6.7 BillionApril 25, 2024 | finance.yahoo.comHospital Care Collaboration and Licensing Deals, 2016-2024: Benchmark Analysis of Deals Entered Into by the World's Leading Biopharma CompaniesJune 18, 2024 | Porter & Company (Ad)Kiss of death from Joe BidenBiden cannot lose this election. A bombshell new documentary exposes how the D.C establishment has engineered an “electoral failsafe” that all but guarantees Democratic victory… not just in 2024 but every future election.April 9, 2024 | finanznachrichten.deAMAG Technology Introduces Symmetry Control RoomApril 8, 2024 | finanznachrichten.deAMAG Technology Announces Company Badge in Google WalletApril 8, 2024 | finance.yahoo.comAMAG Technology Announces Company Badge in Google Wallet(TM)March 4, 2024 | finance.yahoo.comConvergent Therapeutics Appoints Scott Myers as Chairman of its Board of DirectorsFebruary 1, 2024 | uk.finance.yahoo.comGlobal Iron Deficiency Anemia Therapy Market Poised for Growth, Forecasted to Reach $4.6 Billion by 2030June 18, 2024 | Porter & Company (Ad)Kiss of death from Joe BidenBiden cannot lose this election. A bombshell new documentary exposes how the D.C establishment has engineered an “electoral failsafe” that all but guarantees Democratic victory… not just in 2024 but every future election.January 23, 2024 | finanznachrichten.deArizton Advisory & Intelligence: The Global IV and Oral Iron Drugs Market Sees Explosive Growth, the Market to Reach $16.34 Billion by 2029 - AriztonJanuary 12, 2024 | msn.comWhy Vera Therapeutics Stock Soared by 22% This WeekJanuary 9, 2024 | finance.yahoo.comAkebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial OfficerJanuary 8, 2024 | markets.businessinsider.comVera Therapeutics Appoints Robert Brenner As CMODecember 5, 2023 | finance.yahoo.comIntravenous (IV) Iron Formulations Market To Reach USD 6.4 Billion By 2032October 15, 2023 | thestreet.comAMAG's Feraheme Closer to ApprovalOctober 4, 2023 | wsj.comAMAG Austria Metall AGJune 22, 2023 | marketwatch.comContrast Agents Market Size, Share, Emerging Trends, Key Growth Drivers, Challenges and Industry Revenue Outlook 2022-2030June 13, 2023 | finance.yahoo.comLandsdowne Labs Names Bryan Laulicht CEOMay 31, 2023 | finanznachrichten.deLandos Biopharma, Inc.: Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D.May 30, 2023 | finance.yahoo.comLandos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D.May 17, 2023 | marketwatch.comCA 125 Test Market Research | 2023-2030May 17, 2023 | marketwatch.comGlobal Iron Deficiency Anemia Therapy Market Analysis of New Report 2023-2030May 17, 2023 | finance.yahoo.comIntravenous Iron Drugs Global Market Report 2023: Upsurge in Chronic Renal Disease Bolsters DemandMay 11, 2023 | marketwatch.comNanometals Market Research | 2023-2030May 11, 2023 | marketwatch.com2023, Female Sexul Dysfunction Treatment Market | Global Industry Analysis Till 2030May 11, 2023 | marketwatch.comAnemia Treatment Drugs Market Report Help to Grape the Latest Scenario 2023-2030May 10, 2023 | finanznachrichten.deViridian Therapeutics, Inc: Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateSee More Headlines Receive AMAG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AMAG Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/11/2020Today6/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:AMAG CUSIP00163U10 CIK792977 Webwww.amagpharma.com Phone617-498-3300FaxN/AEmployees440Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($6.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-466,460,000.00 Net Margins-74.93% Pretax MarginN/A Return on Equity-16.92% Return on Assets-5.96% Debt Debt-to-Equity Ratio1.13 Current Ratio1.75 Quick Ratio1.45 Sales & Book Value Annual Sales$327.75 million Price / Sales1.46 Cash FlowN/A Price / Cash FlowN/A Book Value$7.37 per share Price / Book1.87Miscellaneous Outstanding Shares34,725,000Free FloatN/AMarket Cap$477.47 million OptionableOptionable Beta0.89 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. William K. Heiden (Age 60)CEO, Pres & Director Comp: $1.28MMr. Anthony Casciano (Age 43)Exec. VP & COO Comp: $625.19kMr. Joseph D. Vittiglio (Age 48)Exec. VP, Gen. Counsel, Chief Bus. Officer & Corp. Sec. Comp: $672.28kMr. Scott D. Myers M.B.A. (Age 54)Pres, CEO & Director Mr. Brian Piekos (Age 46)Exec. VP & CFO Ms. Linda S. LennoxVP of Investor Relations & Corp. CommunicationsMr. Amit VermaVP of MarketingMs. Kelly SchickSr. VP, Chief HR Officer & Head of Corp. EngagementDr. Laura Williams M.D.M.P.H., Sr. VP of Clinical Devel.Mr. Peter BawinSr. VP & GM of Cord Blood RegistryMore ExecutivesKey CompetitorsDynavax TechnologiesNASDAQ:DVAXLigand PharmaceuticalsNASDAQ:LGNDBioCryst PharmaceuticalsNASDAQ:BCRXMannKindNASDAQ:MNKDInnovivaNASDAQ:INVAView All Competitors AMAG Stock Analysis - Frequently Asked Questions How were AMAG Pharmaceuticals' earnings last quarter? AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) issued its earnings results on Monday, May, 11th. The specialty pharmaceutical company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.27. The specialty pharmaceutical company earned $68.66 million during the quarter, compared to the consensus estimate of $64.95 million. AMAG Pharmaceuticals had a negative trailing twelve-month return on equity of 16.92% and a negative net margin of 74.93%. Read the conference call transcript. What other stocks do shareholders of AMAG Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other AMAG Pharmaceuticals investors own include Palatin Technologies (PTN), Bausch Health Companies (BHC), Broadcom (AVGO), Gilead Sciences (GILD), Netflix (NFLX), Energy Transfer (ET), Ford Motor (F), Tesla (TSLA) and NVIDIA (NVDA). This page (NASDAQ:AMAG) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AMAG Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AMAG Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.